Rob Dillard

DocwireNews

Patients with myelofibrosis (MF) who achieve transfusion independence (TI) response (TI-R) on pacritinib show bone marrow reticulin fibrosis (BMF) improvement, according to a study <a href="https://ash.confex.com/ash/2023/webprogram/Paper178753.html" target="_blank" rel="noopener">presented</a> at the 65th ASH Annual Meeting &amp; Exposition.In the PERSIST-2 study, Stephen T. Oh, MD,&nbsp;and colleagues assessed 41 patients with MF on pacritinib (median dose intensity, 100% through week 24) and 18 on ruxolitinib (median daily dose, 10&nbsp;mg at week 24).According to the results, a notably higher proportion of patients treated with pacritinib versus ruxolitinib achieved TI through week 24 (37% vs 6%, respectively; P=.023). The study also found that 44% of patients achieved TI-R, and the proportion of patients who experienced BMF reduction (&ge;1 grade at any point) was significantly greater among patients with TI-R (62.5%) than those with TI-nonresponse (10.0%) on pacritinib.&ldquo;In cytopenic MF patients from PERSIST-2, TI-R on pacritinib was associated with BMF improvement,&rdquo; the researchers concluded. They added that &ldquo;these findings suggest that distinct inhibitory profiles may further distinguish the clinical impact of these treatments. Further studies are warranted to confirm the relationship between BMF reduction and anemia benefit in patients treated with pacritinib.&rdquo;ReferenceOh S, Shammo J, Gupta V, et al. Retrospective analysis of the relationship between transfusion independence and bone marrow fibrosis reduction in patients with myelofibrosis treated with pacritinib versus ruxolitinib. Abstract #4566. Presented at the 65th ASH Annual Meeting &amp; Exposition; December 9-12, 2023; San Diego, California.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Myelofibrosis Patients With Transfusion Independence Show Improved Bone Marrow Fibrosis Reduction

Conference Coverage

Patients with myelofibrosis who achieve transfusion independence response on pacritinib show BMF improvement. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe